Stifel on Viridian Therapeutic (VRDN): 'We think shares can trade in the $40+ range'
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $48.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


